Program Announcement

for the

Defense Health Program
Department of Defense
Congressionally Directed Medical Research Programs

Ovarian Cancer Research Program
Clinical Translational Leverage Award

Funding Opportunity Number: W81XWH-13-OCRP-TLA
Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), June 21, 2013
- Invitation to Submit an Application: August 2013
- Application Submission Deadline: 11:59 p.m. ET, September 11, 2013
- Peer Review: October 2013
- Programmatic Review: December 2013

*This Program Announcement is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.*
# TABLE OF CONTENTS

I. Funding Opportunity Description ................................................................. 3
   A. Program Description .............................................................................. 3
   B. Award Information .................................................................................. 3
   C. Eligibility Information ............................................................................ 4
   D. Funding ................................................................................................... 4

II. Submission Information ............................................................................... 5
   A. Where to Obtain the Application Package ............................................. 5
   B. Pre-Application Submission Content and Form ..................................... 5
   C. Application Submission Content and Form ............................................ 7
   D. Submission Dates and Times ................................................................. 10
   E. Other Submission Requirements ............................................................ 10

III. Application Review Information ............................................................... 10
   A. Application Review and Selection Process .......................................... 10
   B. Application Review Criteria ................................................................. 11
   C. Recipient Qualification ......................................................................... 12
   D. Application Review Dates ..................................................................... 12
   E. Notification of Application Review Results .......................................... 12

IV. Administrative Actions .............................................................................. 13
   A. Rejection ............................................................................................... 13
   B. Modification ......................................................................................... 13
   C. Withdrawal ........................................................................................... 13
   D. Withhold ............................................................................................... 14

V. Award Administration Information ........................................................... 14
   A. Award Notice ........................................................................................ 14
   B. Administrative and National Policy Requirements ............................ 14
   C. Reporting .............................................................................................. 14
   D. Award Transfers .................................................................................. 14

VI. Agency Contacts ....................................................................................... 15
   A. CDMRP Help Desk ............................................................................... 15
   B. Grants.gov Contact Center ................................................................. 15

VII. Application Submission Checklist .......................................................... 16
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2013 (FY13) Ovarian Cancer Research Program (OCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). Appropriations for the OCRP from FY97 through FY12 totaled $196.45 million (M). The FY13 appropriation is $20M. The overall goal of the FY13 OCRP is to eliminate ovarian cancer by supporting innovative, high-impact research. The OCRP’s long-term priorities are as follows:

- Understand precursor lesion/stem cell, microenvironment, and pathogenesis/progression of ovarian cancer;
- Improve performance and reliability of disease markers and imaging toward screening and selecting the best therapeutic approaches;
- Address issues in survivorship;
- Enhance pool of ovarian cancer scientists; and
- Investigate tumor response to therapy including tumor survival, dormancy, cell death, clonal evolution, and tumor heterogeneity.

B. Award Information

The OCRP Clinical Translational Leverage Award mechanism supports the leveraging of existing human-based ovarian cancer resources in translational research to address high-impact research ideas or unmet needs in ovarian cancer, particularly correlative or adjunct analyses associated with clinical trials. Clinical trials are not supported by this award mechanism. Examples of human-based resources include, but are not limited to, biorepositories of clinical specimens, annotated cell lines, epidemiological resources, clinical databases, large transcriptome/proteome/metabolomic datasets, and databases of clinical data and/or metadata. Examples of appropriate research include, but are not limited to, using clinical trial-related samples to better define tumor subtypes, predict therapeutic response, or assess prognosis.

Preliminary data are required.

For the FY13 OCRP, leveraging involves research based on using existing resources in order to amplify potential gains in knowledge of ovarian cancer and then making the results or outcomes available for use by others.

Please note that the Clinical Translational Leverage Award mechanism is designed to support research projects. These studies should be adjunct or correlative to clinical trials. Investigators interested in pursuing the development of well-annotated human-based resources are encouraged to apply for the OCRP FY13 Resource Development Award.

The Congressionally Directed Medical Research Programs (CDMRP) intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to
the General Application Instructions, Appendix 4, Section K.

C. Eligibility Information

- The PI must be at or above the level of Assistant Professor (or equivalent) to be eligible to submit an application.
- Cost sharing/matching is not an eligibility requirement.
- Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

D. Funding

- The maximum period of performance is 2 years.
- The maximum allowable direct costs for the entire period of performance are $250,000 plus indirect costs.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 2 years.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization’s negotiated rate agreement.

Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. For all federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in Section II.C.4 of the General Application Instructions.

For this award mechanism, direct costs may be requested for (not all-inclusive):

- Salary
- Research supplies
- Equipment
- Research-related subject costs (no clinical trials allowed)
- Development of software, databases, websites, and/or other information technology
- Support for multidisciplinary collaborations
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings

The CDMRP expects to allot approximately $1.66M of the $20M FY13 OCRP appropriation to fund approximately four Clinical Translational Leverage Award applications, depending on
the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt System (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-13-OCR-P-CTLA.

B. Pre-Application Submission Content and Form

All pre-application components must be submitted by the PI through the CDMRP eReceipt System (https://cdmrp.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt System by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- Application Information – Tab 1
- Application Contacts – Tab 2
- Collaborators and Conflicts of Interest (COI) – Tab 3

FY13 OCRP Integration Panel (IP) members should not be involved in any pre-application or application. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

- Required Files – Tab 4

Preproposal Narrative (two-page limit): The Preproposal Narrative page limit applies to text and any figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, and cartoons. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive
advantage is prohibited and may result in administrative withdrawal of the application. 

\textit{Note: At this time, eReceipt is unable to read files made with Adobe Acrobat PDFMaker version 9.0 and higher.}

\begin{itemize}
  \item \textbf{Research Question:} Describe the research question and explain why it fills an unmet need or is a high-impact research opportunity in ovarian cancer within the continuum of translational research.
  \item \textbf{Resource:} Describe the existing human-based resource that will be leveraged and why it is uniquely suited to answer the research question. Explain how basing a research project on this existing resource will amplify gains in knowledge of ovarian cancer. Describe how the results of this research effort will be shared with the ovarian cancer research and consumer advocacy communities to maximize leveraging.
  \item \textbf{Impact:} Explain how the research will accelerate the movement of promising ideas toward clinical applications in ovarian cancer, including the potential short-term and long-term impact.
\end{itemize}

\textbf{Pre-Application Supporting Documentation:} The items to be included as supporting documentation for the pre-application are limited to:

\begin{itemize}
  \item References Cited (one-page limit)
  \item Key Personnel Biographical Sketches (four-page limit per individual)
\end{itemize}

\textbf{Submit Pre-Application – Tab 5}

\textit{This tab must be completed for the pre-application to be accepted and processed by CDMRP.}

\textbf{Other Documents Tab}

No additional documents are required.

\textbf{Pre-Application Screening}

\begin{itemize}
  \item \textbf{Pre-Application Screening Criteria}
    To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the OCRP, pre-applications will be screened based on the following criteria:
    \begin{itemize}
      \item How the proposed translational research question fills an unmet need in or will have a high impact in ovarian cancer.
      \item How the existing human-based resource will be leveraged to address the proposed research question.
      \item How the results will be shared with the ovarian cancer research and consumer advocacy communities to maximize leveraging.
      \item How the research will accelerate the movement of promising ideas toward clinical applications in ovarian cancer, including short-term and long-term impact.
    \end{itemize}
  \end{itemize}

\textbf{Notification of Pre-Application Screening Results}

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a
critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity.

C. Application Submission Content and Form

Applications will not be accepted unless the PI has received notification of invitation of invitation.

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

Grants.gov application package components: For the Clinical Translational Leverage Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. SF 424 (R&R) Application for Federal Assistance Form: Refer to the General Application Instructions, Section II.C., for detailed information.

2. Attachments Form

- Attachment 1: Project Narrative (five-page limit): Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and will result in administrative withdrawal of the application.

PIs must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Preliminary data are required. Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and reasoning behind the proposed research, to include relevant literature citations. Explain why the proposed research question fills an unmet need or is a high-impact research opportunity in ovarian cancer within the continuum of translational research. Describe the existing human-based resource that will be leveraged and why it is uniquely suited to answer the research question. Explain how basing a research project on this existing resource will amplify gains in knowledge of ovarian cancer. Explain how the results of this research effort will be shared with the ovarian cancer research and consumer advocacy communities to maximize leveraging and to remove barriers in future ovarian cancer research or patient care.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be attained.

- **Specific Aims:** Concisely explain the project’s specific aims to be supported by this application. If this research project is part of a larger study, present only
tasks that the DoD award would fund.

○ **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail. Address potential problem areas and present alternative methods and approaches. If human subjects or human anatomical samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples.

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. **There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested may result in the removal of those items or administrative withdrawal of the application.**

  ○ References Cited: List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

  ○ List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

  ○ Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

  ○ Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then a copy/copies of the published manuscript(s) must be included in Attachment 2. Extra items will not be reviewed.

  ○ Letters of Organizational Support (no page limit per letter): Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project.

  ○ Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

  ○ Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”
Background: State the research question and present the ideas and reasoning behind the proposed work. Describe the existing human-based resource that will be leveraged and why it is uniquely suited to answer the research question.

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design including appropriate controls.

Impact: Explain how the research addresses an unmet need in or has a high impact on ovarian cancer that will ultimately accelerate the movement of promising ideas toward clinical applications, including the short-term and long-term impact.


The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer advocate community.

Lay abstracts should be written using the outline below:

- Clearly describe, in a manner readily understood by lay persons, the rationale and objective for the proposed work.
  - Do not duplicate the technical abstract.
- Describe the ultimate applicability of the research, including the short-term and long-term impact:
  - Which individuals will it help and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected time it may take to achieve a clinically relevant result?
  - What are the likely contributions of this study to advancing the field of research?

Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.C., for detailed information, including guidance on appropriate SOW formats.

Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf.” Describe in detail why the proposed research effort should be supported, focusing on how it addresses an unmet need or has a high impact on translational research in ovarian cancer, the expected outcomes, and anticipated benefits to ovarian cancer. Explain how the research will accelerate the movement of promising ideas toward clinical applications in ovarian cancer, including the potential short-term and long-term impact.

3. Research & Related Senior/Key Person Profile (Expanded): Refer to the General Application Instructions, Section II.C., for detailed information. Note: Some of the items in this attachment may be made available for programmatic review.

- PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
• PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

• Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”

• Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C., for detailed information.

   • Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C., for detailed information.

D. **Submission Dates and Times**

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet any one of the deadlines will result in application rejection.

E. **Other Submission Requirements**

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a Data Universal Numbering System (DUNS) number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the System for Award Management (SAM) with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.

III. **APPLICATION REVIEW INFORMATION**

A. **Application Review and Selection Process**

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, U.S. Army Medical Research and Materiel Command, based on technical merit, the relevance to the mission of the DHP and OCRP and the specific intent of the award mechanism. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP can be found at [http://cdmrp.army.mil/about/fundingprocess](http://cdmrp.army.mil/about/fundingprocess).
All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a non-disclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.

B. Application Review Criteria

1. Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

   • Research Strategy and Feasibility
     ○ How well the scientific rationale supports the project and its feasibility, as demonstrated by a review and analysis of the literature.
     ○ How well the hypotheses or objectives, experimental design, methods, and analyses have been developed and how well they support completion of the aims.
     ○ How well the PI identifies potential problems and addresses alternative approaches.
     ○ How well the preliminary data support the proposed research.
     ○ How well the research requirements are supported by the availability of and accessibility to facilities and resources including the proposed leveraged resource.

   • Resource Leveraging
     ○ The extent to which this existing human-based resource is uniquely suited to answer the research question.
     ○ Adequacy of the plan for how the resource will be obtained and made available for this research project.
     ○ How the outcomes of this research will be shared with the ovarian cancer community to maximize leveraging, and remove barriers in future ovarian cancer research or patient care.

   • Impact
     ○ How well the proposed research question fills an unmet need in or has high impact on translational research in ovarian cancer.
     ○ How well the research will accelerate the movement of promising ideas toward clinical applications in ovarian cancer, including the potential short- and long-term impact.
In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Personnel**
  - To what extent the research team’s background, experience, and expertise are appropriate to execute the proposed work.
  - To what extent the levels of effort by the PI and other key personnel will ensure success of the proposed work.

- **Environment**
  - Whether the scientific environment is appropriate for the proposed research.
  - To what extent the quality and extent of institutional support are appropriate for the proposed research.

- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influenced the review.

2. **Programmatic Review:** To determine the application’s relevance to the mission of the DHP and OCRP, as well as to make funding recommendations, the following criteria are used by programmatic reviewers:
   
a. **Ratings and evaluations of the peer reviewers**

b. **Relevance to the mission of the DHP and OCRP, as evidenced by the following:**
   - Programmatic relevance
   - Relative impact on ovarian cancer
   - Program portfolio balance
   - Adherence to the intent of the award mechanism

C. **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D. **Application Review Dates**

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.

E. **Notification of Application Review Results**

Each PI and organization will receive notification of the funding recommendation. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.
IV. ADMINISTRATIVE ACTIONS

After receipt of pre-applications from the CDMRP eReceipt System or applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- Submission of an application for which a letter of invitation was not received.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, the PI may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section IV.A., Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- A FY13 OCRP IP member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY13 OCRP IP members can be found at [http://cdmrp.army.mil/ocrp/panels/panels13](http://cdmrp.army.mil/ocrp/panels/panels13).
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the Research & Related Budget exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
• Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
• The PI does not meet the eligibility criteria.

D. **Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

V. **AWARD ADMINISTRATION INFORMATION**

A. **Award Notice**

Awards will be made no later than September 30, 2014. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. **Administrative and National Policy Requirements**

Refer to the General Application Instructions, Appendix 4, Section D, for general information regarding administrative and national policy requirements.

C. **Reporting**

Refer to the General Application Instructions, Appendix 4, Section E, for general information on reporting requirements.

D. **Award Transfers**

Refer to the General Application Instructions, Appendix 4, Section F, for general information on organization or PI changes.
VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through the CDMRP eReceipt System should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507
Email: help@cdmrp.org

B. Grants.gov Contact Center

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726
Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the application package. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-424 (R&amp;R) Application for Federal Assistance Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Attachments Form</td>
<td>Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Supporting Documentation (Support.pdf) as Attachment 2.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Technical Abstract (TechAbs.pdf) as Attachment 3.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Lay Abstract (LayAbs.pdf) as Attachment 4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Statement of Work (SOW.pdf) as Attachment 5.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R &amp; R Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>